** Shares of drug developer Monte Rosa Therapeutics rise 37.22% to $6.84 ** Novartis will pay GLUE $150 million upfront for a global license to develop, manufacture and sell some drug candidates
** GLUE will also be eligible for future payments of up to $2.1 billion in development, regulatory, and sales milestones
** The agreement is expected to accelerate the development of MRT-6160, which is in an early-stage study for immune-mediated conditions
** GLUE stock up ~20% YTD
(Reporting by Sriparna Roy in Bengaluru) ((mailto:Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。